$260.62 Million in Sales Expected for Opko Health Inc. (OPK) This Quarter

Equities research analysts predict that Opko Health Inc. (NASDAQ:OPK) will report $260.62 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Opko Health’s earnings, with the highest sales estimate coming in at $269.90 million and the lowest estimate coming in at $252.30 million. Opko Health reported sales of $263.50 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 1.1%. The business is expected to issue its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Opko Health will report full year sales of $1.03 billion for the current year, with estimates ranging from $1.01 billion to $1.05 billion. For the next fiscal year, analysts forecast that the business will post sales of $1.09 billion per share, with estimates ranging from $1.03 billion to $1.13 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.06. Opko Health had a negative net margin of 31.73% and a negative return on equity of 9.32%. The firm had revenue of $263.69 million during the quarter, compared to analyst estimates of $260.37 million.

OPK has been the subject of a number of analyst reports. ValuEngine raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price objective on shares of Opko Health in a report on Tuesday, May 8th. BidaskClub raised shares of Opko Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 10th. Barrington Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Opko Health in a research note on Wednesday, May 9th. Finally, Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating and set a $4.75 target price for the company in a research note on Wednesday, May 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $10.95.

Shares of OPK traded down $0.08 during mid-day trading on Tuesday, reaching $5.42. The stock had a trading volume of 6,292,497 shares, compared to its average volume of 7,250,249. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.94. Opko Health has a 52-week low of $2.66 and a 52-week high of $7.24.

In related news, CEO Phillip Md Et Al Frost bought 10,000 shares of the stock in a transaction on Friday, May 25th. The stock was bought at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $11,355,118.70. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have acquired 562,719 shares of company stock valued at $2,541,630. 42.74% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the stock. Castleview Partners LLC purchased a new stake in shares of Opko Health during the 1st quarter worth $103,000. SG Americas Securities LLC purchased a new stake in shares of Opko Health during the 2nd quarter worth $136,000. North Star Investment Management Corp. purchased a new stake in shares of Opko Health during the 2nd quarter worth $141,000. RPg Family Wealth Advisory LLC boosted its position in shares of Opko Health by 74.3% during the 2nd quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 13,250 shares in the last quarter. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of Opko Health during the 4th quarter worth $179,000. Hedge funds and other institutional investors own 23.55% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Article: Trading Strategy

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply